Telix Pharmaceuticals (ASX:TLX) said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma (STS), according to a Tuesday statement by the company.
The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography (PET), the statement said.
TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.
The study will inform future therapeutic approaches for treating the disease, the company said.
Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.
Shares of the company fell 3% on market close.